HCM
HUTCHMED (China) LtdCompany with tickers: HCM, HMDCF
CIK
1648257
CUSIP
44842L103
Shares Outstanding
171,950,364
Website
https://www.hutch-med.com
Investor Relations
https://www.hutch-med.com/shareholder-information/investor-faqs/
13F Activity (30d)
16 filings
7 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $548,512,000 | USD | 2025-12-31 | 20-F | 2026-03-05 |
| Cost of Revenue | — | ||||
| Gross Profit | $310,272,000 | USD | 2025-12-31 | 20-F | 2026-03-05 |
| Operating Expenses | — | ||||
| Research & Development | $148,295,000 | USD | 2025-12-31 | 20-F | 2026-03-05 |
| Operating Income | $-39,160,000 | USD | 2025-12-31 | 20-F | 2026-03-05 |
| Net Income | $456,909,000 | USD | 2025-12-31 | 20-F | 2026-03-05 |
| EPS (Basic) | $0.53 | USD/shares | 2025-12-31 | 20-F | 2026-03-05 |
| EPS (Diluted) | $0.52 | USD/shares | 2025-12-31 | 20-F | 2026-03-05 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Segment (USD)
| Component | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|
| Oncology Or Immunology Segment | $26,792,000 | $30,215,000 | $119,610,000 | $163,844,000 | $528,616,000 | $363,365,000 | $285,539,000 |
| Other Ventures Segment | $178,098,000 | $197,761,000 | $236,518,000 | $262,565,000 | $309,383,000 | $266,836,000 | $262,973,000 |
By Geography (USD)
| Component | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| China | $426,409,000 | $484,895,000 | $452,413,000 | $407,454,000 |
| United States And Others | — | $353,104,000 | $177,788,000 | $141,058,000 |
By Product & Service (USD)
| Component | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|
| Goods Distribution | $175,514,000 | $197,761,000 | $236,518,000 | $262,565,000 | $309,383,000 | $266,836,000 | $262,973,000 |
| Marketed Products | $8,113,000 | $11,329,000 | $33,937,000 | $57,057,000 | $83,087,000 | $128,008,000 | $100,637,000 |
| Other Collaboration Royalties Revenue | $2,653,000 | $4,890,000 | $15,064,000 | $26,310,000 | $32,470,000 | $71,041,000 | $68,419,000 |
| Commercialization Services | $2,584,000 | $3,734,000 | $27,428,000 | $41,275,000 | $48,608,000 | $52,485,000 | $45,300,000 |
| License And Collaborations Manufacturing Supply | — | — | — | — | $4,718,000 | $10,392,000 | $31,189,000 |
| Collaboration Research And Development | $15,532,000 | $9,771,000 | $18,995,000 | $23,741,000 | $80,397,000 | $57,968,000 | $27,904,000 |
| Other Collaboration Licensing Revenue | — | — | $23,661,000 | $14,954,000 | $278,855,000 | $43,000,000 | $12,090,000 |
| Research And Development Services | $494,000 | $491,000 | $525,000 | $507,000 | $481,000 | $471,000 | — |